Nouveaux traitements de la maladie de Parkinson

Translated title of the contribution: New treatment of Parkinson disease

F. Vingerhoets, J. Ghika, A. Albanese

Research output: Contribution to journalArticle

Abstract

A wealth of new molecules appeared recently for the treatment of Parkinson's disease. New galenic presentations of L-dopa (biphasic Madopar DR) and COMT inhibitors (tolcapone, entacapone) prolong the effects of L- dopa. New potent, well-tolerated dopaminergic agonists (pergolide, ropinirole, pramipexole, and cabergoline) broaden the possibilities treating early and late phases of the disease and may provide some neuroprotection. Finally subthalamic and pallidal stimulations offer major improvements for advanced patients with drug-resistant fluctuations, but, with uncertainty on long term effects. These procedures should stay in the hands of an experienced team of neurologists and neurosurgeons. Neurotransplantation and use of growth factors are still in preclinical phases.

Original languageFrench
Pages (from-to)1028-1035
Number of pages8
JournalMedecine et Hygiene
Volume56
Issue number2209
Publication statusPublished - May 13 1998

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vingerhoets, F., Ghika, J., & Albanese, A. (1998). Nouveaux traitements de la maladie de Parkinson. Medecine et Hygiene, 56(2209), 1028-1035.